686 related articles for article (PubMed ID: 26705122)
1. Optimizing treatment success in multiple sclerosis.
Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
[TBL] [Abstract][Full Text] [Related]
2. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
3. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
8. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis.
Radü EW; Bendfeldt K; Mueller-Lenke N; Magon S; Sprenger T
Swiss Med Wkly; 2013; 143():w13887. PubMed ID: 24264439
[TBL] [Abstract][Full Text] [Related]
9. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
10. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
[TBL] [Abstract][Full Text] [Related]
11. Optimizing therapy early in multiple sclerosis: An evidence-based view.
Ziemssen T; De Stefano N; Sormani MP; Van Wijmeersch B; Wiendl H; Kieseier BC
Mult Scler Relat Disord; 2015 Sep; 4(5):460-469. PubMed ID: 26346796
[TBL] [Abstract][Full Text] [Related]
12. No evidence of disease activity in multiple sclerosis patients.
Matta AP; Nascimento OJ; Ferreira AC; Magalhães TN; Benevides TP; Kirmse A; Dib JG; Cal H; Orsini M; Araujo LM
Expert Rev Neurother; 2016 Nov; 16(11):1279-1284. PubMed ID: 27352830
[TBL] [Abstract][Full Text] [Related]
13. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
14. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
[TBL] [Abstract][Full Text] [Related]
15. Brain health: time matters in multiple sclerosis.
Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
[TBL] [Abstract][Full Text] [Related]
16. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
17. Disease modifying therapies for relapsing multiple sclerosis.
Wingerchuk DM; Weinshenker BG
BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatment of multiple sclerosis.
Hart FM; Bainbridge J
Am J Manag Care; 2016 Jun; 22(6 Suppl):s159-70. PubMed ID: 27356025
[TBL] [Abstract][Full Text] [Related]
19. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
[TBL] [Abstract][Full Text] [Related]
20. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
Mayssam EN; Eid C; Khoury SJ; Hannoun S
Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
